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Abstract
Background. Contrast-enhanced ultrasonography (CEUS)
is a novel imaging technique that is safe and applicable on
the bedside. Recent developments seem to enable CEUS to
quantify organ perfusion. We performed an exploratory
study to determine the ability of CEUS to detect changes
in renal perfusion and to correlate them with effective renal
plasma flow.
Methods. CEUS with destruction-refilling sequences was
studied in 10 healthy subjects, at baseline and during
infusion of angiotensin II (AngII) at low (1 ng/kg/min)
and high dose (3 ng/kg/min) and 1 h after oral captopril
(50 mg). Perfusion index (PI) was obtained and compared
with the effective renal plasma flow (ERPF) obtained by
parallel para-aminohippurate (PAH) clearance.
Results. Median PI decreased from 188.6 (baseline) to 100.4
with low-dose AngII (47%; P < 0.02) and to 66.1 with
high-dose AngII (65%; P < 0.01) but increased to 254.7
with captopril (135%; P > 0.2). These changes parallelled
those observed with ERPF, which changed from a median of
672.1 mL/min (baseline) to 572.3 (low-dose AngII,15%, P
< 0.05) and to 427.2 (high-dose AngII, 36%, P < 0.001)
and finally 697.1 (captopril, 14%, P < 0.02).
Conclusions. This study demonstrates that CEUS is able to
detect changes in human renal cortical microcirculation as
induced by AngII infusion and/or captopril administration.
The changes in perfusion indices parallel those in ERPF as
obtained by PAH clearance.
Keywords: angiotensin II; contrast-enhanced ultrasound; effective renal
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Introduction
Background
The methods currently available to assess and monitor
renal perfusion are either very inaccurate or not applicable
in human and particularly in critically ill patients. The
physiological gold standard to estimate the renal plasma
flow is the calculation of PAH clearance which has long
been recognized as inaccurate in oliguria and acute kidney
injury [1, 2]. Doppler studies have been demonstrated to
be unreliable [3]. The use of scintigraphy or magnetic
resonance imaging (MRI) is limited by equipment avail-
ability, costs and their requirement for extensive and
prolonged patient manipulation. These methods anyway
only give information about the global organ perfusion
(macrocirculation) and not about the microcirculation
whose importance is being increasingly recognized in the
literature [4–6]. A method enabling the evaluation of renal
microcirculation, which would be applicable in every day
clinic routine and especially in the intensive care unit,
would greatly improve the understanding of the patho-
physiology of acute kidney injury.
Contrast-enhanced ultrasonography (CEUS) is a novel
imaging technique associating low mechanical index
(MI) ultrasonography and microbubble-based contrast
agents [7]. CEUS has found numerous applications in
particular for the characterization of focal liver lesions
and in the assessment of myocardial perfusion. Recently
developed techniques have been proposed to quantify
blood flow within an organ with CEUS [8]. They make use
of the purely intravascular distribution of the microbubbles
and their sensitivity to high-power acoustic pulses to obtain
so-called destruction-refilling sequences, from which some
parameters proportional to blood flow can be derived. Initially
validated for themyocardium[8, 9], these techniques are being
applied to other organs such as the kidney [10, 11]. The val-
idation of CEUS as a diagnostic tool in monitoring renal per-
fusion is still under development but several studies have
shown promising results [12, 13].
To confirm the ability of CEUS to detect changes in
cortical microcirculation in humans, we decided to perform
CEUS with destruction-refilling sequences in 10 healthy
volunteers at baseline, during infusion of angiotensin II
(AngII, an arterial vasoconstrictor) and after oral intake
of captopril (an arterial vasodilator).
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Materials and methods
Subjects
Twelve healthy normotensive male subjects without any history of cardio-
vascular, renal or endocrine disease were recruited. A full medical history,
a complete physical examination, ECG and blood tests for routine chemistry
and haematology as well as a standard renal echography to ensure adequate
visualization of both kidneys were performed before inclusion.
The study protocol was approved by the local hospital ethical commit-
tee and written informed consent was obtained from each subject.
Study design
The general scheme of the experiment is depicted in Figure 1. CEUS and
para-aminohippurate (PAH) clearance study, as the gold standard for es-
timating effective renal plasma flow (ERPF), were performed in parallel.
In order to maintain a high urinary output (hourly micturition required),
the subjects were asked to drink 5 mL/kg of mineral water on arrival and
150 mL every hour. A peripheral venous catheter was inserted in each arm
for infusion of the contrast agent and the study drugs. A baseline CEUS
with destruction-refilling sequences was performed. The infusion of AngII
(Clinalfa; Bachem AG, Offenburg, Germany) was then started at a rate
of 1 ng/kg/min under close monitoring of the arterial blood pressure. The
peak effect of AngII is achieved within minutes [14]. We allowed a 45-min
equilibration period before performing the second CEUS study. The AngII
infusion was then increased to 3 ng/kg/min. After 45 min of infusion at
this rate, the third CEUS was performed. The AngII infusion was then
stopped and 50 mg of captopril (Captopril Mepha; Mepha Pharma AG,
Aesch, Switzerland) were administered orally. Since, after oral adminis-
tration, the peak plasma concentration of captopril is obtained in <1 h
[15], we performed the last CEUS 1 h after the administration.
The subjects were monitored for an additional hour and then
discharged.
Renal perfusion measurement with contrast-enhanced ultrasound
CEUS of the kidney was performed with an Aplio XG (Toshiba Medical,
Tokyo, Japan) using a 3.5 MHz probe and a dedicated low MI (low
acoustic power of the ultrasound) mode (MI ¼ 0.1). Both kidneys were
initially visualized and the most accessible chosen to perform the study.
The contrast agent used was Sonovue (Bracco SpA, Milan, Italy). It was
injected as a continuous infusion with a dedicated syringe pump (Vue-
Ject; Bracco SA, Milano, Italy) at a rate of 0.5 mL/min. Infusion was
started 2 min before examination to reach a steady state. During this time,
an optimal long axis view of the kidney was obtained by placing the
transducer probe over the lower back with the subject in supine position.
Image depth, focus, gain and frame rate were optimized at the beginning of
each experiment and held constant during the study. At each time point,
three consecutive destruction-refilling sequences (with 15 s refilling time)
were performed. Destruction was obtained by applying five pulses at high
MI (flash) and refilling observed at low MI. DICOM clips were acquired
and exported via DVD-R.
Data analysis
In each series, we analysed the sequence associated with the less move-
ments artefact and with the larger cortical visualization. These sequences
were analysed blindly, using prototype software called SonoPerf (Bracco
Research SA, Geneva, Switzerland). After loading the DICOM sequences,
three regions of interest (ROI) were drawn in the renal cortex (Figure 2).
Very strict criteria were used to accept a ROI. The ROI had to be located
within the outer cortex of the kidney and could only include microvascu-
lature (which can be verified by the total absence of bubbles immediately
after flash). After flash, the perfusion curve had to start from a level close to
zero and display the expected replenishment shape not to be mistaken for
noise. Lastly, a quality-of-fit index was observed to ensure appropriate signal
quality. To minimize the effects of ultrasound attenuation and beam non-
uniformity, the three ROI’s were drawn at approximately the same depth.
The software then determined for each ROI the mean transit time
(mTT), the regional blood volume (RBV) and calculated a perfusion index
(PI; PI ¼ RBV/mTT) which is deemed to be proportional to blood flow
[16]. These measurements were repeated for each sequence: at baseline,
low-dose AngII, high-dose AngII and after captopril.
The two readers (A.S. and L.H.) selected independently the ROIs to be
analysed in each sequence, using the same above-mentioned criteria. These
data were analysed independently and used for confirmation purposes.
PAH clearance
The infusion of PAH was primed with a bolus and started 2 h before the
first CEUS to achieve a predetermined serum PAH concentration (calcu-
lated according to the subjects weight). Baseline blood and urine samples
were obtained before starting AngII infusion. The next samples were
obtained 1 h after adjusting the AngII infusion rate and 1 h after captopril
to allow PAH serum levels to reach a new steady state.
The samples were analysed blinded to sequence time by the research
laboratory of the nephrology unit. ERPF was evaluated by calculation of
renal PAH clearance using the classic formula (RPF ~ ClPAH¼UPAH3V/
PPAH) [17].
Statistical analysis
From previous studies [18], the ERPF was expected to drop by 40% after
AngII infusion and to increase by 20% after captopril intake. Based on
these values, a statistical significance of 0.05 with a power of 0.8 was
expected to be obtained with 10 subjects. We decided to recruit 12 to allow
for some technical problems to occur.
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Fig. 1. General plan of the study. AngII low, angiotensin II 1 ng/kg/min; AngII high, angiotensin II 3 ng/kg/min; PAHu, urinary PAH concentration;
PAHp, plasmatic PAH concentration.
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As the condition of normally distributed data is not fulfilled the non-
parametric Wilcoxon signed rank-sum test was used to compare to base-
line the results obtained at the different time points. These comparison
statistics were carried out with STATA/ IC 10.0 for Windows (StataCorp,
College Station, TX).
The data obtained by the two readers at each time point were compared
using an analysis of variance test or the Kruskall–Wallis test depending on
the homogeneity of variances (homoscedacity). These analyses were gener-
ated with the help of StatgraphicsPlus 5.1 (Manugistic SA, Rockville, MD).
Results are expressed as means for normally distributed data and as
median and interquartile range (IQR) for non-normally distributed data.
A P-value of <0.05 was considered to be significant.
Results
General
Of the 12 subjects enrolled, the full protocol could be per-
formed for 10 of them. One subject was excluded because of
an accidental change in the echography machine settings mak-
ing the results non-comparable with the others and the other
because no urine sample could be obtained on AngII infusion
making urinary PAH measurement impossible. The mean age
of the 10 subjects that completed the study was 23 (21 to 25)
years, the mean body mass index was 24.4 (19.2–32) kg/m2
and the mean serum creatinine level, 85 (75–104) lmol/L.
Baseline serological values were all within normal.
AngII infusion, captopril ingestion and Sonovue infu-
sion were well tolerated and no adverse event was
recorded. The mean arterial pressure (Figure 3) increased
with the high dose of AngII by 11 mmHg on average
(maximum increase 18 mmHg) and returned to baseline
once the infusion was stopped. It then remained unchanged
after the administration of captopril.
Adequate visualization of the kidneys was obtained and
CEUS easily performed in all subjects. The exact duration
was not recorded but due to the study design, CEUS had to
be performed within a 15 min time frame, which proved to
be easily feasible in a setting where everything was already
pre-installed.
Three adequate ROI could be drawn in all but four
sequences (90%) where only two were deemed acceptable.
Perfusion indices
The median perfusion indices obtained by CEUS are shown
in Figure 4. A statistically significant decrease in PI was
observed on AngII infusion as compared to baseline from
a median value of 188.6 (baseline, IQR 136.9) to 100.4
(IQR 88.7, 45%; P < 0.02). They further decreased on
AngII dose to 66.1 (IQR 83.8; 65%; P < 0.01). After cap-
topril administration, we observed a nonstatistically signifi-
cant increase in PI to 254.7 (IQR 336.9;135%; P > 0.2).
Interobserver variability
The readings performed by the main reader were compared
to those of a second reader for confirmation purposes. A
non-parametric test (Kruskall–Wallis) was used and
Fig. 2. Screenshot from Sonoperf illustrating localization of ROI and determining perfusion indices. Only PI is shown. Upper left corner: native
DICOM sequence allowing placement of ROI (colour ovals). The green ROI around the whole kidney is used for reference and calculation only; it’s size
and shape does not modify the numerical results. Upper right corner: parametric imaging mode improving ROI placement quality. Bottom right and left:
replenishment curves; actual data (clear curve) and fitted curved (bold curve). Colours relate to the corresponding ROI.
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showed no statistically significant differences between the
three measurements at each time point since all P-values
were >0.05.
Effective renal plasma flow
The results of the PAH clearance studies are depicted in
Figure 5. Due to sampling issues, no data could be obtained for
Volunteers 8 and 9 at the AngII low-dose experimental point.
The median ERPF was 672.1 mL/min (IQR 147.7) on
baseline. It decreased to 572.3 mL/min (IQR 162.4) on
AngII low dose (15%, P < 0.05) and to 427.2 mL/min
(IQR 58.5) during high-dose infusion (36% from base-
line, P < 0.001) of AngII. It increased to 697.1 mL/min
(IQR 206.1) after oral administration of captopril (14%
from baseline; P < 0.02).
Relationship between PI and ERPF
As presented in Figure 6, the changes in PI parallelled those
observed in ERPF as measured by PAH clearance.
ERPF and PI decreased during low-dose AngII infusion,
by 15% (ERPF) and by 47% (PI) of their baseline values.
During high-dose AngII infusion, they decreased even
further by 36% (ERPF) and 65% (PI). Similarly, after oral
captopril intake and compared to baseline, a minimal (4%)
Fig. 3. Mean arterial pressure. AngII low, angiotensin II 1 ng/kg/min; AngII high, angiotensin II 3 ng/kg/min; Vol, volunteer.
Fig. 4. Perfusion indices. AngII Low: angiotensin II 1 ng/kg/min, AngII High: angiotensin II 3 ng/kg/min, Vol: volunteer. Scale has been adapted for
Volunteer 3 and is 310 the other.
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increase in ERPF was observed, while the PI increase
(135%) was not statistically significant. Detailed results
are presented in Figure 7.
The Spearman test demonstrated a correlation between
the two parameters (r ¼ 0.57, P ¼ 0.002).
Discussion
In this study, we have shown, in 10 healthy volunteers, that
CEUS with the SonoPerf software is able to reliably de-
tect changes in the renal microcirculation when associated
to a 15% decrease in ERPF. Our results also showed that a
further decrease in ERPF (36% in total) was associated
with a further decrease of the PI (65% in total). On the
other hand, a 4% increase in ERPF after captopril resulted
in a non-significant 35% increase in the PI.
All study drugs were well tolerated. The mean arterial
pressure increased as expected and returned to normal once
AngII infusion was stopped and captopril administered.
CEUS studies with destruction-refilling sequences were
performed in a very short time. There was no technical
difficulty to visualize the kidneys. The duration of exami-
nation never exceeded 15 min.
Microcirculation in the critically ill has been well
studied by way of orthogonal polarization spectral
(OPS) imaging [19]. This technique, applied to the sub-
lingual mucosa, allowed to demonstrate marked altera-
tions in microcirculation in sepsis particularly in the
patients with the worst outcome [6, 20]. It also revealed
alterations after cardiopulmonary bypass correlated with
lactate elevation [21] and in severe heart failure correlated
with survival [22]. CEUS can add to techniques like OPS
by enabling another type of assessment of the microcircu-
lation. Its applicability to other organs and relative ease
of execution makes CEUS potentially usable in the every
day clinical routine.
Following Wei et al. [8], initial description of a techni-
que for myocardial blood flow quantification using high MI
and intermittent imaging mode, several authors attempted
Fig. 5. ERPF (estimated by PAH clearance). ERPF expressed in millilitres per minute, AngII Low: angiotensin II 1 ng/kg/min, AngII High: angiotensin
II 3 ng/kg/min, Vol: volunteer.
Fig. 6. Comparison between perfusion indices and ERPF. ERPF expressed
in millilitres per minute, AngII Low: angiotensin II 1 ng/kg/min, AngII
High: angiotensin II 3 ng/kg/min. Data expressed as median value.
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Fig. 7. Perfusion indices (PI) and ERPF in 10 volunteers at baseline, after infusion of 1 ng/kg/min of AngII (AngII low), after infusion of 3 ng/kg/min of
AngII (AngII high) and after oral captopril (captopril). Vol ¼ volunteer with the number for each volunteer next to it; ERPF expressed in millilitres per
minute, AngII Low: angiotens in II 1 ng/kg/min, AngII High: angiotensin II 3 ng/kg/min. Data expressed as median value.
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to use CEUS to study organ microcirculation [9, 23, 24]. In
the kidney, the first animal study was reported by Schlosser
et al. [12] who showed that the acquisition of destruction-
refilling sequences was also feasible using low-MI real-
time imaging and allowed the differentiation between
macro- and microcirculation. Wei et al. [9] then reported
an excellent correlation (r ¼ 0.82, P < 0.001) between the
measurement of renal perfusion as obtained by CEUS and
the flow measured by a probe directly placed on the renal
artery when the flow was modified by either mechanical
blockade or dopamine infusion. To our knowledge, the first
report of human renal blood flow (RBF) quantification by
CEUS was made by Hosotani et al. [13] who showed a
significant correlation between RBF obtained by CEUS
and radionuclide scanning values using technetium-99m
mercaptoacetyltriglycine (Tc-99m MAG3) (r ¼ 0.67, P ¼
0.005), as well as PAH clearance (r ¼ 0.69, P ¼ 0.005) in
16 patients with chronic kidney disease of various causes.
Later, Kishimoto et al. [11] reported an increased micro-
bubble velocity and fractional vascular volume during an
infusion of dopamine, which was correlated with an in-
crease in regional blood flow. More recently, Kalantarinia
et al. [23] used CEUS to monitor the expected increase in
renal blood flow after a high-protein meal in healthy vol-
unteers. They reported a 42.8% increase in the A 3 b
parameter (representing renal blood flow) 2 h following a
high-protein meal.
All these studies consistently showed promising results
and concluded that CEUS could be a precise and reprodu-
cible way of evaluating renal perfusion. However, they
present several limitations. Most of them make use of the
method of Wei et al. [8] for quantifying renal blood flow.
This method was experimentally well correlated but suffers
from several flaws because it quantifies video after log
compression and hence produces results, which depend
on the US system used and user setting. A new approach
developed by Arditi et al. [16] was shown to allow more
objective estimates of flow when applied to data first line-
arized to be proportional to local ultrasound contrast agent
concentration. This formalism was implemented within the
Windows-based software SonoPerf used in the present
study. SonoPerf performs relative-flow quantification.
Sonoperf includes a tool for motion compensation and
proposes a parametric imaging mode allowing to display
colourimetric maps of any of the computed parameters, this
feature being very helpful for precise ROI drawings.
The most remarkable result obtained in our study is the
ability of CEUS to detect, on the basis of a PI measurement,
a decrease in ERPF as small as 15%. Overall, the observed
changes in PI induced by AngII were all statistically
significant despite the small number of subjects. A non-
significant increase in PI was observed, when associated
with a very small (4%) increase in ERPF. PI and ERPF
were not expected to be linearly correlated since they
actually measure different parameters (macro- versus
0microcirculation). However, their parallel evolution estab-
lishes CEUS as a sensitive and reliable tool to assess renal
perfusion changes. This study also showed that CEUS can
be performed in a very limited time (<15 min). This finding
is especially relevant if CEUS has to be applied in the
intensive care unit.
Apart from the small number of subjects, this study
has some limitations worth discussing. Firstly, the compar-
ison between ERPF and PI cannot be strict since these two
techniques actually compare different parameters, respec-
tively, total renal blood flow and regional cortical flow.
Thus, the study drugs can affect the renal microvasculature
and the renal artery differently. However, in the absence
of a generally recognized gold standard to measure renal
cortical blood flow, we believe that even an imperfect
comparator can provide a useful sense of changes in renal
cortical blood flow as obtained for instance in response to a
pharmacological stimulation.
Secondly, CEUS with SonoPerf provides a relative
measurement of perfusion. The results are not expressed
in millilitre per minutes but as perfusion indices that need
to be compared to a baseline or another tissue reference.
This is illustrated by the highly heterogeneous range of
PI values at baseline (from 46 to 918) and the important
IQR. This limitation has to be considered when designing
studies relying on this technique. However, this study
shows that changes are interpretable and trends in the evo-
lution of perfusion indices provide valuable indications.
Heterogeneity of measurements was also present within
each individual subject although less pronounced than
across subjects. This might very well represent local
micro-heterogeneities [24] but can also be related to im-
precisions in the placement of ROI. To minimize this
parameter, we applied strict standardized criteria for ROI
selection, as shown in the Materials and Methods section.
Three ROI’s were drawn for each experimental time point
and the results averaged. This approach limits the number
of areas available for analysis but allowed us to minimize
heterogeneity of measurement as confirmed by the good
interobserver agreement.
Medullary perfusion indices and more importantly corti-
comedullary ratios of PI would probably be of great impor-
tance in the clinical setting. However, we were not able
to obtain consistent data in the medullary segment due to
wide local heterogeneity, possibly linked to the presence
of numerous arteries and veins in this non-homogeneous
zone.
Despite initial concerns, recent publications now estab-
lish CEUS as a very safe procedure [25–28], even appli-
cable to critically ill patients. Since it is a fast, sensitive
and reliable technique applicable at the bedside, CEUS is
probably well designed to study renal microcirculation in
humans and might be promising particularly in critically
ill patients, in whom other techniques are not applicable.
Conclusion
This study demonstrates that CEUS is able to detect
changes in human renal cortical microcirculation as in-
duced by AngII infusion and/or captopril administration.
CEUS is a fast, sensitive and reliable technique to assess
renal microcirculation. Further studies are necessary to es-
tablish its feasibility and its role in the evaluation of renal
perfusion in situations such as acute kidney injury.
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